NIH RECOVER
-
Research updates, June 9
A new study published in Alzheimer’s and Dementia found more evidence of alterations associated with Alzheimer’s disease in people with Long COVID. Notably, scientists identified a larger choroid plexus, a region of blood vessels in the brain, as well as reduced cerebral blood flow.
-
Why are RECOVER’s first round of Long COVID clinical trials failing?
The U.S.’s flagship Long COVID research program has received over a billion dollars in funding and had years of input from people with the disease. But its first round of clinical trials are failing, at least in the results out so far.
-
RECOVER’s first round of clinical trials are failing. Will the next phase be better?
The NIH studies found that Paxlovid, ivabradine, and computer games did not significantly improve symptoms of Long COVID. Further analysis that may help future research research has not yet been released.
-
Research updates, March 31
The heart failure drug Ivabradine did not significantly improve symptoms for people with Long COVID and postural orthostatic tachycardia syndrome (POTS), according to preliminary results that RECOVER researchers recently shared at a conference.
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
One NIH study will test low-dose naltrexone, while other upcoming trials will test larozitide and taurine.
-
New RECOVER-TLC trials won’t enroll until summer. Nearly two years after the program’s launch.
The RECOVER-Treating Long COVID initiative is set to begin enrolling participants in new clinical trials this summer, which will mark nearly two years after the National of Institutes of Health (NIH) effort launched with promises to deliver greater urgency for this chronic disease impacting tens of millions of Americans.
-
Severe people may hold answers to Long COVID. They must be included in research.
People with the most severe symptoms represent the most clinically urgent population, yet they remain absent from the evidence base that guides care. Their exclusion is not a procedural oversight but a scientific failure, and correcting it is essential for any program committed to understanding the full spectrum of the disease.
-
Research updates, November 25
A new review paper summarizes the vast global costs of Long COVID. Public health researcher Amit Bansal from the University of Bergen conducted an economic literature analysis and determined that Long COVID is estimated to have an average annual burden of at least $1 trillion globally each year.
-
Research updates, November 11
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
-
Kennedy’s HHS commits to Long COVID, but without clear funding
Following two roundtable discussions with leading researchers and government officials — but limited patient engagement — HHS announced a public awareness campaign and medical resource platform
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance